Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and
tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic
lupus erythematosus (SLE).